期刊
DERMATOLOGIC THERAPY
卷 35, 期 11, 页码 -出版社
WILEY
DOI: 10.1111/dth.15794
关键词
adverse drug reaction; GIRAE; inflammatory skin diseases; psoriasis; psoriasis treatment; secukinumab
类别
资金
- Universita Politecnica delle Marche within the CRUI-CARE Agreement
Real-world data on secukinumab's gastrointestinal-related adverse events (GIRAE) in psoriatic patients are limited. A retrospective study was conducted to review medical records of patients treated with secukinumab for plaque psoriasis at Ospedali Riuniti Umberto I clinic in Ancona. The study found that secukinumab was an effective and safe drug for plaque psoriasis treatment, with minimal gastrointestinal adverse events.
Real-world secukinumab gastrointestinal-related adverse events (GIRAE) data in psoriatic patients treated with secukinumab are lacking. A descriptive, retrospective study was performed by reviewing the medical records of patients who received secukinumab for plaque psoriasis for at least 1 year and who made a follow-up visit to the dermatology clinic of Ospedali Riuniti Umberto I in Ancona between December 1, 2021, and March 31, 2022. The patients' medical history and clinical data were collected at T0, before treatment, and at T1, corresponding to the last follow-up visit. Special attention was given to gastrointestinal adverse events (GIRAE). A total of 108 patients were included in the study. At baseline median PASI was 14.8 (range 2.2-27, SD 6.1), and median DLQI was 9.3 (5-16, SD 2.6). The median PASI for treated patients was 0.7 (0-3, SD 0.8; p < 0.00) 1and median DLQI was 0.3 (0-1, SD 0.5; p < 0.001). At T1 54/114 patients (50%) reached PASI100, of the other 54, 48 (88.9%) reached PASI 90 while the other six discontinued for secondary ineffectiveness. Only three patients reported a GIRAE (diarrhea), however, when screened, no IBD was found. Consistent with data in the literature, secukinumab is an effective and safe drug for the treatment of plaque psoriasis also in a real-life experience context. There should be no concern in choosing the drug for fear of possible IBDs-related GIRAE if there is no personal history or familiarity for IBDs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据